Click on image to view larger version.

Figure 2 Time to First Major CV Event by Treatment in Patients With CKD and With Normal eGFR at Baseline

In patients with chronic kidney disease (CKD) at baseline, intensive lipid lowering with atorvastatin 80 mg resulted in a 32% relative reduction in risk of major cardiovascular (CV) events compared with atorvastatin 10 mg (p = 0.0003). In patients with normal or near-normal estimated glomerular filtration rate (eGFR) at baseline, a smaller but significant 15% relative reduction in risk of major CV events was observed with atorvastatin 80 mg (p = 0.049). ARR = absolute risk reduction; CI = confidence interval; HR = hazard ratio; NNT = number needed to treat.